Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28181
Title: | A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. | Authors: | Johnson D.W.;Brown F.;Hawley C.M.;Leary D.;Noble E.;Campbell S.B.;Isbel N.M.;Mudge D.W.;Van Eps C.L.;Barraclough K.A. | Institution: | (Barraclough, Hawley, Leary, Noble, Campbell, Isbel, Mudge, Van Eps, Johnson) Department of Nephrology, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia (Brown) Department of Nephrology, Monash Medical Centre, Melbourne, Australia (Hawley, Johnson) Australasian Kidney Trials Network, School of Medicine, University of Queensland, Brisbane, Australia | Issue Date: | 4-Dec-2012 | Copyright year: | 2012 | Publisher: | Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom) | Place of publication: | United Kingdom | Publication information: | Nephrology Dialysis Transplantation. 27 (11) (pp 4146-4153), 2012. Date of Publication: November 2012. | Abstract: | BackgroundPreliminary clinical evidence suggests that heme iron polypeptide (HIP) might represent a promising, novel oral iron supplementation strategy in chronic kidney disease. The aim of this multi-centre randomized controlled trial was to determine the ability of HIP administration to augment iron stores in darbepoetin (DPO)-treated patients compared with conventional oral iron supplementation.MethodsAdult peritoneal dialysis (PD) patients treated with DPO were randomized 1:1 to receive two capsules daily of either HIP or ferrous sulphate per os for 6 months. The primary outcome measure was transferrin saturation (TSAT). Secondary outcomes comprised serum ferritin, haemoglobin, DPO dose and responsiveness, and adverse events.ResultsSixty-two patients were randomized to HIP (n = 32) or ferrous sulphate (n = 30). On intention-to-treat analysis, the median (inter-quartile range) TSAT was 22 (16-29) in the HIP group compared with 20 (17-26) in controls (P = 0.65). HIP treatment was not significantly associated with TSAT at 6 months on multivariable analysis (P = 0.95). Similar results were found on per-protocol analysis and subgroup analysis in iron-deficient patients. Serum ferritin levels at 6 months were significantly lower in the HIP group (P = 0.003), while the cost of HIP was 7-fold higher than that of ferrous sulphate. No other differences in secondary outcomes were observed.ConclusionsHIP showed no clear safety or efficacy benefit in PD patients compared with conventional oral iron supplements. The reduction in serum ferritin levels and high costs associated with HIP therapy suggest that this agent is unlikely to have a significant role in iron supplementation in PD patients. © The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/ndt/gfs372 | PubMed URL: | 22962411 [http://www.ncbi.nlm.nih.gov/pubmed/?term=22962411] | ISSN: | 0931-0509 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/28181 | Type: | Article | Type of Clinical Study or Trial: | Randomised controlled trial |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.